Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.
Rong FanHatice SatilmisNiels VandewalleEmma VerheyePhilip VlummensAnke MaesCatharina MuylaertElke De BruyneEline MenuHolly EvansAndrew ChantryNathan De BeuleDirk HoseMarie TörngrenHelena ErikssonKarin VanderkerkenKen MaesKarine BreckpotKim De VeirmanPublished in: Journal for immunotherapy of cancer (2023)
Our study provides novel insights in the dual therapeutic effects of the immunomodulator tasquinimod and fosters its evaluation in combination therapy trials for MM patients.
Keyphrases
- combination therapy
- end stage renal disease
- multiple myeloma
- signaling pathway
- induced apoptosis
- newly diagnosed
- ejection fraction
- poor prognosis
- bone marrow
- prognostic factors
- peritoneal dialysis
- acute myeloid leukemia
- immune response
- bone mineral density
- cell proliferation
- binding protein
- cell death
- patient reported outcomes
- endoplasmic reticulum stress
- body composition